Description: The author provides an overview of the Chinese health care system from its beginnings in in 1949 to the present day launching of the most comprehensive reform ever.

Description: Two nonactuarial experts representing opposing health care reform solutions present their alternative views. From Record of Society of Actuaries Vol. 20, No. 3A.

Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.

Description: In this session actuarial and benefit design issues of various health care reform proposals will be identified. An update on task force activities will be presented. The relative richness of benefits will be discussed. Key benefit components such as mental illness coverages will be featured. From Record of Society of Actuaries Vol. 20, No. 3A.

Description: This presents the results of a May 2010 survey by the Society of Actuaries SOA asking members of the SOA Health Section for their opinions on ways to bend the cost curve in light of the Patient Protection and Affordable Care Act ACA, the new health reform law passed in March 2010.

Description: This research report examines the potential implications of the risk mitigation programs – risk adjustment, reinsurance, and risk corridors – established under The Patient Protection and Affordable Care Act.

Description: Panelists present the positions being staked out by the political parties, the likelihood of passage of any of the proposed legislation, and the potential impacts on the health care market of the various proposals. From the Record of the Society of Actuaries, Volume 27, No. 3, Session 131PD.

Description: 2001 SOA Annual Meeting, New Orleans. Health care cost trends have substantially increased in the past two years. Panelists discussed the factors contributing to these increased trends, the prospect for further increases in the future, and national health care issues.

Description: Panel examines the actuarial, business, clinical, and ethical issues attached to physician-owned health plans in which the physicians are both providers and investors. From the Record of the Society of Actuaries, Vol. 24, No. 3.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.